Is CareDx (CDNA) Fully Valued After Its Medicare Coverage Win?

CareDx (CDNA) is back in focus after Medicare finalized a Local Coverage Determination that confirms reimbursement for its molecular transplant surveillance tests across kidney, heart, and lung, with defined test limits by organ and by year.

See our latest analysis for CareDx.

The LCD decision comes after a sharp share price move, with CareDx’s 7 day share price return of 33.41% and 90 day share price return of 85.09% contributing to a 1 year total shareholder return of 200.94%, although the 5 year total shareholder return is down 53.49%, hinting that recent momentum is building off a much lower base.

If this kind of move has your attention, it can be useful to see what else is driving interest in transplant and organ health technology. You can start with 39 healthcare AI stocks.

Bulls see the Medicare decision and strong recent share price momentum as a reset for CareDx, while bears point to past share price declines and ongoing losses. How does the current valuation stack up against those competing stories?

Most Popular Narrative: 38% Overvalued

CareDx last closed at $38.37, while the most followed narrative puts fair value at $27.80, so that framework sees the recent rally as moving ahead of its assumptions.

The analysts have a consensus price target of $27.8 for CareDx based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $21.0.

Read the complete narrative.

Want to see what has to happen for that fair value to make sense? The narrative leans on faster earnings improvement, firmer margins, and a richer future earnings multiple than the sector typically commands.

Result: Fair Value of $27.80 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the CareDx story also carries real pressure points, including potential revenue hits from bundled payments and its heavy reliance on key transplant testing lines if reimbursement shifts again.

Find out about the key risks to this CareDx narrative.

Another View: CareDx DCF Signals a Very Different Price

The analyst narrative frames CareDx as 38% overvalued at $38.37 versus a $27.80 fair value, but the Simply Wall St DCF model points in the opposite direction. On that view, the stock trades at roughly a fifth of an estimated $193.76 future cash flow value. Which story do you think rests on assumptions you trust more?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With mixed signals around CareDx, consider reviewing the data yourself, weighing both sides, and deciding how you feel about the stock’s balance of 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond CareDx?

If CareDx has sharpened your interest, do not stop here. Broaden your watchlist with other focused ideas that could suit very different approaches to risk and return.

• Target potential mispricings by reviewing companies in the 45 high quality undervalued stocks and see which stocks currently trade below their assessed worth.
• Strengthen your income lineup by scanning the 9 dividend fortresses and identify stocks offering higher yields with an eye on consistency.
• Protect your capital more deliberately by filtering for companies in the 80 resilient stocks with low risk scores and concentrate on stocks with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com